NATICK, Mass., Nov. 9 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved its new Artisan(TM) 2x8 Surgical Lead for use with the Precision(R) Spinal Cord Stimulation (SCS) system. It is the first surgical or "paddle" lead developed by Boston Scientific's Neuromodulation Group, providing new populations of chronic pain sufferers with access to the Precision system's innovative treatment for chronic pain of the limbs, back or trunk.
"The Artisan lead addresses the needs of those patients who require the stability of a surgical lead and the benefits of precise stimulation," said John Oakley, M.D., a neurosurgeon in Billings, Montana, who specializes in pain treatment. "The Precision system, combined with the Artisan lead, will broaden the number of patients I can treat with neurostimulation."
The Artisan 2x8 Surgical Lead features 16 tightly spaced contacts in a two-column array. This lead connects to the Precision(R) neurostimulator, a small implantable device that uses a patented rechargeable battery system. The Precision IPG (implantable pulse generator) enables each of the 16 Artisan lead contacts to be independently powered. This new lead is designed to deliver focused stimulation for pain management.
"The Artisan Surgical Lead will make the Precision SCS system accessible to approximately 20 percent of additional chronic pain sufferers who require the features of a paddle lead," said Jeffrey Greiner, President of Boston Scientific's Neuromodulation Group. "Physicians in the neuromodulation market are now fully equipped to manage pain patients with our advanced technology."
About the Precision SCS System
The Precision System is an implantable neuromodulation device that delivers low-level electrical current to the spinal cord, masking pain signals as they travel to the brain. It is the smallest rechargeable neurostimulator available, and the only one capable of sculpting or shaping pain-masking stimulation intended to target pain more precisely.
Patients interested in Precision technology should speak to their pain management physician or visit http://www.ControlYourPain.com for more information.
About Boston Scientific Corporation
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. Boston Scientific's Neuromodulation Group is a global leader in the development of implantable, high-technology neurostimulation devices that include new treatments for deafness and chronic pain. For more information, please visit http://www.bostonscientific.com and http://www.advancedbionics.com.
This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with clinical trials, the regulatory approval process, commercialization of new technologies, reimbursement policies and practices, intellectual property, competitive product offerings, and other factors described in the Company's filings with the Securities and Exchange Commission.
CONTACT: Milan Kofol 508-650-8569 Investor Relations Boston Scientific Corporation Paul Donovan 508-650-8541 Media Relations Boston Scientific Corporation Boston Scientific Corporation
CONTACT: Milan Kofol, Investor Relations, +1-508-650-8569, or PaulDonovan, Media Relations, +1-508-650-8541 both of Boston ScientificCorporation
Web site: http://www.bostonscientific.com//
